Longboard Pharmaceuticals, Inc.

NasdaqGM:LBPH Stock Report

Market Cap: US$788.1m

Longboard Pharmaceuticals Management

Management criteria checks 3/4

Longboard Pharmaceuticals' CEO is Kevin Lind, appointed in Mar 2020, has a tenure of 4.08 years. total yearly compensation is $2.05M, comprised of 29.7% salary and 70.3% bonuses, including company stock and options. directly owns 0.9% of the company’s shares, worth $7.06M. The average tenure of the management team and the board of directors is 2.1 years and 3.3 years respectively.

Key information

Kevin Lind

Chief executive officer

US$2.1m

Total compensation

CEO salary percentage29.7%
CEO tenure4.1yrs
CEO ownership0.9%
Management average tenure2.1yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03
Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25
We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10
Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28
We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27
Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals EPS beats by $0.29

May 10

CEO Compensation Analysis

How has Kevin Lind's remuneration changed compared to Longboard Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$610k

-US$54m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$2mUS$572k

-US$44m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$36m

Mar 31 2022n/an/a

-US$32m

Dec 31 2021US$875kUS$547k

-US$28m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$2mUS$332k

-US$14m

Compensation vs Market: Kevin's total compensation ($USD2.05M) is below average for companies of similar size in the US market ($USD3.43M).

Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.


CEO

Kevin Lind (47 yo)

4.1yrs

Tenure

US$2,053,804

Compensation

Mr. Kevin R. Lind serves as President and Chief Executive Officer at Longboard Pharmaceuticals, Inc. since March 2020 and also serves as its director since January 2020. He serves as Director at Ceek Women...


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Lind
President4.1yrsUS$2.05m0.90%
$ 7.1m
Brandi Roberts
Executive VP & CFO3.3yrsUS$1.03m0%
$ 0
Randall Kaye
Executive VP & Chief Medical Officer2.1yrsUS$1.16m0%
$ 0
Chadwick Orevillo
Executive VP & Head of Operationsno datano datano data
Megan Knight
VP & Head of Investor Relationsno datano datano data
Steven Spector
Executive VP3.3yrsno datano data
Anne Danks
VP & Head of Nonclinical Research & Development1.3yrsno datano data
Gus Cardenas
VP & Head of Quality Assurance2.1yrsno datano data
Marco Peters
VP & Head of Translational Science2.1yrsno datano data
Dewey McLin
VP & Head of Medical Affairs2.3yrsno datano data
Nuggehally Srinivas
VP and Head of Clinical Pharmacology & Pharmacometrics1.3yrsno datano data
Michael Scannell
VP and Head of Chemistry & CMCless than a yearno datano data

2.1yrs

Average Tenure

53.5yo

Average Age

Experienced Management: LBPH's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Lind
President4.3yrsUS$2.05m0.90%
$ 7.1m
Phillip Schneider
Independent Director3.3yrsUS$121.80k0%
$ 0
Casey Lynch
Independent Director3.2yrsUS$112.80k0%
$ 0
Paul Sekhri
Independent Chairman of the Board3.3yrsUS$145.81k0%
$ 0
Vincent Aurentz
Independent Director4.2yrsUS$109.34k0%
$ 0
Corinne Le Goff
Independent Director3.1yrsUS$114.81k0%
$ 0
Jane Tiller
Independent Director2.4yrsUS$108.33k0%
$ 0

3.3yrs

Average Tenure

58yo

Average Age

Experienced Board: LBPH's board of directors are considered experienced (3.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.